Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
AssigneeHoffman-La Roche Inc.
InventorsWerner Bollag, Michael Klaus, Paola Panina-Bordignon, Francesco Sinigaglia
Life of this patent
Estimating the term…
Abstract
Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.
Claims19
A method of treating a T-helper cell type 2-mediated immune disease or a disease mediated by T-helper cell type 2-related cytokines, which comprises administering to a subject having a T-helper cell type 2-mediated immune disease or a disease mediated by T-helper cell type 2-related cytokines an effective amount of a compound selected from the group consisting of retinoid antagonists, pharmaceutically acceptable salts of retinoid antagonists, and pharmaceutically acceptable hydrolyzable esters of such retinoid antagonists and their salts, with the proviso that the T-helper cell type 2-mediated immune disease is not atopic dermatitis.
Dependencies are inferred from the claim text.